Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Day One Biopharmaceuticals Inc
NASDAQ DAWN
Data sourced from
and
and
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) 3 year CAGR for the quarter ending March 31, 2024: 12.83%
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) 3 year CAGR is 12.83% for the quarter ending March 31, 2024, a -34.64% change year over year. Shares (Diluted, Weighted) represent the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) for the quarter ending March 31, 2023 was 71,972,888.00, a 23.28% change year over year.
-
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) for the quarter ending March 31, 2022 was 58,382,444.00, a -3.24% change year over year.
-
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) for the quarter ending March 31, 2021 was 60,337,415.00, a 43.55% change year over year.
-
Day One Biopharmaceuticals Inc Shares (Diluted, Weighted) for the quarter ending March 31, 2020 was 42,030,978.00.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DAWN
| CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
| IPO Date | May 27, 2021 |
| Location | United States |
| Headquarters | 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 174 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Key trends
Similar companies
Acumen Pharmaceuticals Inc
NA
NA
Eledon Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email